Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

After a thorough process, management are pleased to undertake this pivotal step for GMP production of PRP for the upcoming Phase 1 FIH clinical study
May 19, 2026 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium

Matisse Pharmaceuticals announces U.S. FDA clearance of the company’s Investigational New Drug (IND) application for isupartob sodium
May 19, 2026 03:30 ET | Source: Mestag Therapeutics

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
May 19, 2026 02:00 ET | Source: Khondrion B.V.

Khondrion Announces First Patient Dosed in Phase II Study Targeting Debilitating Post-COVID Fatigue

Khondrion announced that the first patient has been dosed in the Phase II SON4PEM study evaluating sonlicromanol in Post-COVID.
May 18, 2026 08:30 ET | Source: Medidata Solutions, Inc.

Medidata’s Second Annual AI Report Shows a Shift from Pilots to Enterprise Adoption with 72.9% of Early Adopters Seeing a Reduction in Study Timelines

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today released its second annual report...
May 15, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).
May 11, 2026 08:00 ET | Source: Jabez Biosciences, Inc.

Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026

Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 ...
May 11, 2026 07:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a...
May 10, 2026 05:09 ET | Source: WhiteSwell

WhiteSwell Announces Primary Clinical Trial Results Simultaneously at Heart Failure 2026 Congress and in European Journal of Heart Failure related to the DELTA-HF Study in Acute Decompensated Heart Failure

GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech company pioneering a new treatment paradigm for acute decompensated heart failure (ADHF), today announced...
May 08, 2026 16:05 ET | Source: Longeveron

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.